Growth hormone-releasing hormone analog

CJC-1295 (no DAC)

A 2026 review lists the half-life of CJC-1295 without DAC (Mod GRF 1-29) as not reported in human studies and finds no peer-reviewed human study of it; the app lists about 30 minutes.1

Moderate evidence (the app's grade)Get the app

Level after one dose

CJC-1295 (no DAC) after one dose: 50% at ~30 min, 25% at 60 min, 12.5% at 90 min.

Drawn from the half-life in the app's model, ~30 min. The model's figures

CJC-1295 (no DAC) is listed in the app as Mod GRF 1-29, an analog of growth hormone-releasing hormone (GHRH). A 2026 review in Frontiers in Endocrinology describes CJC-1295 as "a synthetic analogue of GHRH, designed to stimulate pituitary GH secretion", where GH is growth hormone.1 Knoop and colleagues of the German Sport University Cologne, in Analytical and Bioanalytical Chemistry in 2016, give the sequence of CJC-1295 as YdADAIFTQSYRKVLAQLSARKLLQDILSR-NH2 with a monoisotopic mass of 3365.9 Da; the lowercase d marks the D-alanine at position 2.2

The same review states that "CJC-1295 without DAC" "remains essentially uncharacterised in the peer-reviewed human literature" and that "no controlled clinical studies have directly evaluated this compound in humans".1 It puts the compound in the last of its four evidence tiers, tier D, and says the compounds in that tier "have no peer-reviewed human studies and are supported only by preclinical extrapolation and grey-literature user narratives".1

A search of PubMed on 16 November 2026 for CJC-1295 in the title or summary text returned 35 records. Two match the publication-type filter for clinical trials, both from 2006: Teichman and colleagues, and Ionescu and Frohman.3,4 The review cites Teichman and colleagues as evidence for CJC-1295 with DAC, and Ionescu and Frohman describe a form that "binds permanently to endogenous albumin after injection (half-life = 8 d)".1,4

The app grades the evidence for this compound as moderate; the grade is the app's own and differs from the review's tier D placement above.

Dominikowski and colleagues write that CJC-1295 "includes four amino-acid substitutions that increase resistance to proteolytic degradation" compared with native human GHRH.1 Knoop and colleagues list sermorelin, GRF 1-29, as YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH2; set beside the CJC-1295 sequence above, the two differ at positions 2, 8, 15 and 27.2

DAC stands for drug-affinity complex. The review states that "the DAC modification enables binding to circulating albumin, markedly prolonging exposure".1 Jetté and colleagues of ConjuChem Inc. described an albumin-binding compound in Endocrinology in 2005 as "a tetrasubstituted form of hGRF(1-29) with an added N epsilon-3-maleimidopropionamide derivative of lysine at the C terminus"; in normal male Sprague Dawley rats given it subcutaneously it "showed a 4-fold increase in GH area under the curve over a 2-h period compared with hGRF(1-29)", and it was "present in plasma beyond 72 h".5

The review states that "Two main variants circulate commercially in the off-label market".1 Two analytical papers describe structures that fit those two variants. Timms and colleagues, in Drug Testing and Analysis in 2019, describe CJC-1295 as "a 30 amino acid peptide-based drug" with "a reactive maleimidopropionic acid group", which fits the albumin-binding variant.6 Henninge and colleagues of the Norwegian Doping Control Laboratory, in 2010, identified in an unknown preparation "a 29 amino acid peptide with a C-terminal amide function" whose sequence was "consistent with a peptide currently marketed under the name CJC-1295", which fits the variant without DAC.7

The review's table gives the primary biological effect of the no-DAC form as increased, pulsatile release of endogenous GH, with the entry marked "inferred from GRF 1-29 study". Its reference for that entry is Aitman and colleagues, Peptides, 1989, a study in men of GHRH(1-29) and one other analog, not of CJC-1295 without DAC.1,8 Aitman and colleagues write that the analog's "greatly enhanced activity" in the rat "is not found in humans", a species difference.8

3

Pharmacokinetics

Values from the Milligram app's model.

Half-life
~30 min
Bioavailability
95%
Typical dose
100–300 mcg/day
Route
SubQ
Time to peak
~15 min

The table sets the app's figures beside what the sources cited report. The review's table lists no pharmacokinetic figure for CJC-1295 without DAC from a human study.1

Table 3.1Pharmacokinetics5 rows
ParameterApp's figureReported in the sources cited
Half-lifeAbout 30 minutes (0.5 hours).CJC-1295 without DAC: the review's table lists the half-life as "not reported in human studies".1 Related analogs in 10 men during a 90-minute intravenous infusion: a disappearance half-time of 6.7 +/- 0.5 minutes for D-Ala2-GHRH-(1-29)-NH2 and 4.3 +/- 1.4 minutes for GHRH-(1-29)-NH2 (P < 0.05), Soule and colleagues, 1994.9 Long-acting form: an estimated half-life of 5.8 to 8.1 days, Teichman and colleagues, 2006.3 In rats given 0.1 mg of CJC-1295 intravenously, Knoop and colleagues (who do not name the form; the sequence they list has 29 residues) detected the intact peptide in plasma 2, 4 and 8 hours later; they state that "only qualitative results were obtained and that no pharmacokinetic interpretation was conducted".2
Time to peakAbout 15 minutes.None of the sources cited reports a time to peak for CJC-1295 without DAC.
Bioavailability95%.None of the sources cited reports a bioavailability figure for CJC-1295 without DAC.
RouteSubcutaneous injection (SubQ).The review's table states: "No peer-reviewed clinical studies in humans have reported the route of administration".1
Duration of activityAbout 2 hours.None of the sources cited reports a duration of activity for CJC-1295 without DAC.
4

Human studies

No row in the table is a human study of CJC-1295 without DAC. The rows are the human studies the sources describe for the long-acting form and for related GHRH analogs, each labeled with the compound it measured.

Table 4.1Human studies6 rows
Study and yearDesignPeopleDose and lengthMain result
Teichman and colleagues, 2006 (long-acting CJC-1295)3Two randomized, placebo-controlled, double-blind, ascending-dose trials of 28 and 49 daysHealthy adults aged 21 to 61; the number is not in the summary textSubcutaneous: one of four ascending single doses in the first trial; two or three weekly or biweekly doses in the secondAfter a single injection, dose-dependent increases in mean plasma GH of 2- to 10-fold for 6 days or more and in mean IGF-I of 1.5- to 3-fold for 9 to 11 days; estimated half-life 5.8 to 8.1 days; no serious adverse reactions were reported.
Ionescu and Frohman, 2006 (long-acting CJC-1295)4GH sampled every 20 minutes over an overnight 12-hour period before and 1 week after one injectionHealthy men aged 20 to 40; the number is not in the summary textA single injection of 60 or 90 microg/kgGH pulse frequency and magnitude unaltered; trough GH 7.5-fold higher (P < 0.0001), mean GH 46% higher (P < 0.01), IGF-I 45% higher (P < 0.001); no significant differences between the two doses; IGF-I increases did not correlate with any GH secretion parameter.
Sackmann-Sala and colleagues, 2009 (long-acting CJC-1295)10Serum proteins before and 1 week after one injection, no placebo group described, by two-dimensional gel electrophoresis and mass spectrometry11 healthy men, BMI below 25, aged 20 to 34A single injection of 60 to 90 microg/kg (CJC-1295 supplied by ConjuChem Inc.)Two protein spots fell (an apolipoprotein A1 isoform and a transthyretin isoform) and three rose (beta-hemoglobin, a C-terminal fragment of albumin, and a mix of an immunoglobulin fragment and another albumin fragment); IGF-1 levels showed a linear relationship with the spot of immunoglobulin and albumin fragments.
Soule and colleagues, 1994 (D-Ala2 analog)9Constant intravenous infusion of each analog, blood sampled during and after10 normal men25 ng/kg per minute for 90 minutesMetabolic clearance 21 +/- 1.2 mL/kg per minute for the D-Ala2 analog against 39.7 +/- 3.9 for GHRH-(1-29)-NH2 (P < 0.001); disappearance half-time 6.7 +/- 0.5 against 4.3 +/- 1.4 minutes (P < 0.05).
Aitman and colleagues, 1989 (Ac-D-Tyr1,D-Ala2 analog)8GHRH(1-29)NH2 compared with the analog in normal male volunteersThe number is not in the summary text3 microg/kg subcutaneously, a submaximal dosePeak GH response and GH area under the curve were similar for the native peptide and the analog; no significant differences in peak immunoreactivity, area under the curve or plasma disappearance rates.
Corpas and colleagues, 1992 (GHRH-(1-29), sermorelin)11Two 14-day subcutaneous treatments in random order with a 14-day break; young men as comparison10 old men (68.0 +/- 6.2 years) and 9 young men (26.2 +/- 4.1 years)0.5 mg or 1 mg twice daily for 14 daysDose-related increases; against old basal values, mean 24-hour GH (P < 0.001) and IGF-I (P < 0.005) differed only at the high dose; phosphate levels increased (P < 0.05); no effect on fasting glucose, urinary C-peptide, blood pressure or chemistry and hematology profiles.

Deeper analysis: Knoop and colleagues, 2016

Knoop and colleagues of the German Sport University Cologne and the C.E.R. Groupe laboratory in Belgium built a plasma test for four GHRHs, including CJC-1295, for doping control.2 They write that "because of their D-Ala2 modification, no analogous metabolites of CJC-1293 and CJC-1295 were observed", and that in the rat work sermorelin and CJC-1293 "were found to be readily biotransformed especially when compared to CJC-1295".2 The CJC-1295 samples came from rats, in which "no anticipated metabolite was confirmed"; the only human sample described was collected after subcutaneous injection of sermorelin (Geref) to one healthy male volunteer, and it held a sermorelin metabolite, GHRH3-29.2

The authors' stated limitation is that "further studies are however required and warranted to account for potential species-related differences in metabolism and elimination of the target analytes".2 The paper's funding line names the World Anti-Doping Agency and the Partnership for Clean Competition, and the authors state that they "have no conflicts of interest to declare".2

Deeper analysis: the 2006 trials of the long-acting form

Teichman and colleagues report their two trials in the Journal of Clinical Endocrinology and Metabolism in 2006, with "peak concentrations and area under the curve of GH and IGF-I" as the main outcome measures.3 After multiple doses, "mean IGF-I levels remained above baseline for up to 28 d", and the authors conclude that CJC-1295 "was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg".3 Three of the six authors (Lawrence, Gagnon and Castaigne) are affiliated with ConjuChem, Inc., two (Teichman and Neale) with WinPharm Associates and one (Frohman) with the University of Illinois.12 The PubMed record gives no funding statement and lists no limitations.3

Ionescu and Frohman of the University of Illinois at Chicago conclude that CJC-1295 "increased trough and mean GH secretion and IGF-I production with preserved GH pulsatility".4 The PubMed record lists a grant from NCRR (NIH HHS) and no limitations.4 Sackmann-Sala and colleagues drew their 11 men from a larger cohort described in an earlier paper; the PubMed record lists grants from NIDDK and NIA (NIH HHS).23 They compared the same men before and after one injection, with no placebo group described. Of 192 spots detected, 97 were present in all subjects and five differed, two with P values of 0.047 and 0.049; no other significant correlation with IGF-1, lowest GH or mean GH was reported. They suggest that the proteins they identified "represent potential biomarkers of GH and/or IGF-1 action".10

Deeper analysis: Dominikowski and colleagues, 2026

The review is the source of the statements above about CJC-1295 without DAC. It is a narrative review: PubMed, Google Scholar and the Cochrane Library were searched for English-language publications from January 1989 to January 2026.1 The authors write that the search "was not conducted against a pre-registered protocol, did not follow PRISMA reporting standards, and did not incorporate a formal risk-of-bias appraisal of individual included studies".1 They state that the work "received no external funding", with the publication charge partly paid by a foundation of the Karol Marcinkowski University of Medical Sciences in Poznan.1

5

Doses reported in studies

None of the sources cited reports a dose of CJC-1295 without DAC given to a person in a study. The app lists a typical dose of 100 to 300 mcg per day by subcutaneous injection, which is the app's figure and not a dose from a study.

Table 5.1Doses reported in studies5 rows
SourceDoseFrequencyLength
Teichman, 2006 (long-acting CJC-1295, subcutaneous; healthy adults aged 21 to 61)3One of four ascending single doses in the first trial; the conclusion names doses of 30 or 60 microg/kgTwo or three weekly or biweekly doses in the second trial28 and 49 days
Ionescu and Frohman, 2006 (long-acting CJC-1295)460 or 90 microg/kgSingle injectionSampling 1 week after the injection
Corpas, 1992 (GHRH-(1-29), subcutaneous; 10 old men)110.5 mg or 1 mgTwice daily14 days each
Aitman, 1989 (Ac-D-Tyr1,D-Ala2 analog, subcutaneous; normal male volunteers)83 microg/kgNot stated in the summary textNot stated in the summary text
Review of online sources for CJC-1295 without DAC1100 to 200 microg per injection, subcutaneous1 to 2 times dailyCycle lengths are also listed in the review's table

The last row is not a study. The review takes it from a bodybuilding-related forum, with a blog post by Swolverine as its reference, and states that such protocols are presented "explicitly as anthropological and behavioural descriptors of unregulated self-administration patterns, not as clinical guidance".1

None of the sources cited attributes side effects specifically to the no-DAC form. FDA reports serious adverse events for CJC-1295 without naming a form.15 The review's table for the compound gives "No peer-reviewed human studies" and, beside it, "theoretical oncologic concern" for mitogenic GH and IGF-1 signalling, with "no established clinical carcinogenic signal".1

For the long-acting form, Teichman and colleagues state that "no serious adverse reactions were reported" and that it was "safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg".3

Mavrych and colleagues write that CJC-1295 "showed promise in Phase 2 trials, but commercial development ceased following a trial participant's death, though it was deemed unrelated to the study drug".13 The review's reference for that sentence is Teichman and colleagues, 2006, whose summary text reports no serious adverse reactions.13,3 The registry entry for ConjuChem's phase 2 trial of "CJC 1295" in people with HIV-associated visceral obesity, listing an enrollment of 120, shows the status terminated, gives no reason and does not name the form.14

Statements by regulators

FDA's category 2 page says of CJC-1295: "FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited".15 The Australian TGA's April 2026 advisory says of unapproved peptide products in general that the adverse events and other concerns it received include, among others, "severe allergic reactions, requiring doses of adrenaline and hospitalisation", "systemic inflammatory response syndrome (SIRS)" and "musculoskeletal injuries, including plantar fasciitis and Achilles tendinitis", and names CJC-1295 among its examples.16 The review's adverse-effect list covers the GH-axis peptides as a group: prolactin and cortisol elevations, appetite changes, dysglycaemia, fluid retention syndromes, myalgia or arthralgia and injection-site reactions. It states that "ACTH/cortisol and prolactin elevations are largely a feature of earlier ghrelin-mimetic GHRPs (GHRP-2, GHRP-6, hexarelin)", its table marks GHRH analogues "sparing" for ACTH/cortisol and prolactin, and it attributes none of these effects to CJC-1295 without DAC.1

The app lists IGF-1, blood glucose and insulin as markers. In the long-acting-form studies the measured outcomes were GH and IGF-I, and the summary texts of those studies do not mention blood glucose or insulin.3,4

Corpas and colleagues, who gave GHRH-(1-29) rather than CJC-1295, report that it "did not affect fasting glucose, urinary C-peptide, blood pressure, or chemistry and hematology profiles" in 10 old men over 14 days, and that "Phosphate levels increased (P less than 0.05) during GHRH treatment".11

Dominikowski and colleagues write that "neither CJC-1295 variant is approved as a therapeutic agent by major regulatory authorities (e.g., FDA, EMA)".1 The table gives what each body's page or list says about CJC-1295; none of the three separates the forms with and without DAC.

Table 8.1Regulatory and anti-doping status3 rows
BodyWhat it states about CJC-1295
FDA, category 2 page (content current as of 22 April 2026)15Listed under "Bulk drug substances nominated but withdrawn", a list FDA describes as substances "previously in category 2 of the interim policies" that were "withdrawn by the nominators"; compounded drugs containing CJC-1295 "may pose risk for immunogenicity for certain routes of administration" and "may have complexities with regard to" "peptide-related impurities and API characterization".
WADA 2026 Prohibited List17Named as an example ("e.g.") in S2.2.4, with CJC-1293, sermorelin and tesamorelin, among growth hormone-releasing hormone analogues; class S2 is "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)".
Australian TGA, safety advisory of 13 April 202616Names CJC-1295 among examples of unapproved peptide products, which "have not been assessed by the TGA for safety, quality or effectiveness".

The WADA list states that "all prohibited substances in this class are non-Specified Substances".17 Memdouh and colleagues, in Drug Testing and Analysis in 2021, studied in vitro metabolism of four GHRH analogs, listing CJC-1295 and "CJC-1295 with drug affinity complex" separately,.18 They write that although there is evidence of use of these analogs "based on admissions and intelligence, they do not appear to have been found in anti-doping samples by WADA accredited laboratories".18

Whether the half-life, time to peak, bioavailability and duration the app lists for CJC-1295 (no DAC) have been measured in people is not described in the sources cited: the review's table lists the half-life as not reported in human studies, and none of the other sources reports the others.1

A search of PubMed on 16 November 2026 for "Mod GRF" in the title or summary text returned 0 records. A search for CJC-1295 with "no DAC" or "without DAC" in any field returned 2 records: the 2026 review above and Timms and colleagues' 2026 ELISA for CJC-1295 in horse plasma, which describes the form with a drug affinity complex.1,19

Villegas Meza and colleagues state in a 2026 review that growth hormone axis secretagogues including CJC-1295 "remain investigational, with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions".20 Tewari and colleagues, in a 2026 scoping review of 6 peptides including CJC-1295, state that "Human clinical studies were limited to a handful of investigations, most lacking robust controls or rigorous study designs".21

Van Hout and Hearne analysed 23 online discussion threads on female use of CJC-1295 in Substance Use & Misuse in 2016. They report that "choice to use CJC-1295 centered on weight loss, muscle enhancement, youthful skin, improved sleep, and injury healing", which describes reasons given in forums and does not measure effects; the summary text does not say which form was meant.22 Dominikowski and colleagues note "uncertainty surrounding product composition, dose, and stacking practices in unregulated supply chains".1

What is CJC-1295 (no DAC)?

CJC-1295 without DAC, listed in the app as Mod GRF 1-29, is an analog of growth hormone-releasing hormone (GHRH).1 A 2026 review states that no controlled clinical studies have directly evaluated it in humans.1

What is the half-life of CJC-1295 (no DAC)?

The app lists the half-life of CJC-1295 (no DAC) as about 30 minutes, and a 2026 review's table lists it as not reported in human studies.1 In men, the disappearance half-time was 6.7 minutes for D-Ala2-GHRH-(1-29)-NH2 and 4.3 minutes for GHRH-(1-29)-NH2 in an intravenous infusion study, which measured related analogs and not CJC-1295.9

What is the difference between CJC-1295 with DAC and without DAC?

A 2026 review states that "the DAC modification enables binding to circulating albumin, markedly prolonging exposure".1 The review lists an estimated half-life of about 5.8 to 8 days for the DAC form in healthy adults, and for the no-DAC form no peer-reviewed human study.1

Has CJC-1295 (no DAC) been studied in humans?

A 2026 review states that "no controlled clinical studies have directly evaluated this compound in humans".1 A search of PubMed on 16 November 2026 for CJC-1295 with "no DAC" or "without DAC" in any field returned 2 records, that review and a 2026 horse plasma assay; the two records matching the clinical-trial filter are 2006 papers on the long-acting form.19,3

Is CJC-1295 (no DAC) banned by WADA?

The WADA 2026 Prohibited List names CJC-1295 as an example in S2.2.4, under class S2, headed "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)".17 The list applies to athletes under the World Anti-Doping Code, came into effect on 1 January 2026, and does not separate the forms with and without DAC.17

Is CJC-1295 (no DAC) approved by the FDA?

A 2026 review states that "neither CJC-1295 variant is approved as a therapeutic agent by major regulatory authorities (e.g., FDA, EMA)".1 FDA's category 2 page lists CJC-1295 under "Bulk drug substances nominated but withdrawn", a list of substances previously in category 2 that were withdrawn by the nominators.15

What are the side effects of CJC-1295 (no DAC)?

None of the sources cited attributes side effects specifically to the no-DAC form; the review's table lists "No peer-reviewed human studies" for its safety signals.1 FDA's category 2 page says it has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction, without naming a form, and that available clinical data are limited.15 Teichman and colleagues report no serious adverse reactions in their trials of the long-acting form.3

Is CJC-1295 (no DAC) the same as sermorelin?

No: the sequences differ at positions 2, 8, 15 and 27.2 Sermorelin is GRF 1-29, which the review says was previously FDA-approved and marketed as Geref, with the approvals withdrawn effective 18 June 2009; the review states that FDA determined Geref was not withdrawn for reasons of safety or effectiveness.1

12

References

  1. Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne) 2026. PMC13322892
  2. Knoop A, et al. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Anal Bioanal Chem 2016. PMC4830873
  3. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006. PMID 16352683
  4. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006. PMID 17018654
  5. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005. PMID 15817669
  6. Timms M, et al. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Test Anal 2019. PMID 30489688
  7. Henninge J, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal 2010. PMID 21204297
  8. Aitman TJ, et al. Bioactivity of growth hormone releasing hormone (1-29) analogues after SC injection in man. Peptides 1989. PMID 2546126
  9. Soule S, et al. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. J Clin Endocrinol Metab 1994. PMID 7962295
  10. Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res 2009. PMC2787983
  11. Corpas E, et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 1992. PMID 1379256
  12. Crossref. Publisher record of author affiliations for Teichman SL, et al., J Clin Endocrinol Metab 2006 (DOI 10.1210/jc.2005-1536). Crossref record
  13. Mavrych V, et al. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Front Aging 2026. PMC13095733
  14. ConjuChem. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Evaluate the Efficacy and Safety of CJC 1295 Administered for 12 Weeks in HIV Infected Patients With HIV Associated Visceral Obesity. ClinicalTrials.gov NCT00267527. NCT00267527
  15. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026). FDA page
  16. Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 April 2026. TGA advisory
  17. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA 2026 list
  18. Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal 2021. PMID 34665524
  19. Timms M, et al. Detection of CJC-1295 in Equine Plasma by ELISA. Drug Test Anal 2026. PMID 42876013
  20. Villegas Meza AD, et al. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS Rev 2026. PMID 42160466
  21. Tewari K, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med 2026. PMID 42578445
  22. Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse 2016. PMID 26771670
  23. Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res 2009 (PubMed record). PMID 19386527